<i>Ras</i>Protooncogene Activation in Acute Myeloid Leukemia and Related Disorders

Needleman, Samuel W.

doi:10.3109/10428199109068110

“…The human ras genes encode p21 proteins that appear to play an important role as second messengers in tyrosine kinase receptor-mediated signal transduction (95) These have been the subject of a number of reviews (5,92-94).…”

Section: The Second Hypothesis Is That Loss Of a Single Allele Leads mentioning

confidence: 99%

The Process of Leukemogenesis

Irons¹,

Stillman²

1996

Environmental Health Perspectives

View full text Add to dashboard Cite

Leukemias are monoclonal diseases that arise from cells in the hematopoietic stem and progenitor cell compartment. Consistent with emerging models of carcinogenesis, leukemogenesis is an evolutionary process that involves multiple independent genetic and epigenetic events. Over the last half-century a predominant paradigm has emerged to describe leukemia developing secondary to alkylating drug therapy or exposure to benzene in which progressive dysplastic changes, accompanied by a distinct pattern of clonal cytogenetic abnormalities, give rise to acute myelogenous leukemia. Characterization of these clonal chromosomal aberrations, together with observed alterations in other growth-promoting genes, provides a useful framework for studying chemical leukemogenesis and for use in understanding the origins and development of leukemia in general.

show abstract

“…This discussion will focus only on a small number of these genes. The human ras genes encode p2l proteins that appear to play an important role as second messengers in tyrosine kinase receptor-mediated signal transduction (95). It has been hypothesized that ras mutations may feature prominently in the development of s-AML (96).…”

Section: Regulation Of Hematopoiesismentioning

confidence: 99%

“…However, what role ras mutations play in the development of either de novo or s-AML remains uncertain. In a large number of studies, ras protooncogene activation, principally N-RAS, has been variously reported to occur in about 25% of cases of de novo AML (92,95). However, clonal chromosomal aberrations have been demonstrated to precede ras involvement in the evolution of the disease (97,98) and, when identified, ras mutations tend to be present only in subclones of the leukemic cells (97,99).…”

Section: Regulation Of Hematopoiesismentioning

confidence: 99%

The process of leukemogenesis.

Irons

¹

,

Stillman²

1996

Environ Health Perspect

View full text Add to dashboard Cite

Leukemias are monoclonal diseases that arise from cells in the hematopoietic stem and progenitor cell compartment. Consistent with emerging models of carcinogenesis, leukemogenesis is an evolutionary process that involves multiple independent genetic and epigenetic events. Over the last half-century a predominant paradigm has emerged to describe leukemia developing secondary to alkylating drug therapy or exposure to benzene in which progressive dysplastic changes, accompanied by a distinct pattern of clonal cytogenetic abnormalities, give rise to acute myelogenous leukemia. Characterization of these clonal chromosomal aberrations, together with observed alterations in other growth-promoting genes, provides a useful framework for studying chemical leukemogenesis and for use in understanding the origins and development of leukemia in general.

show abstract